NKY: The invested company for injectable human interleukin-2 has been approved for clinical use

NKY announced that its investee company, Beijing Liangyuan Biopharmaceutical Research Co., Ltd., has obtained implied approval for domestic clinical trials of its injectable human interleukin-2, indicated for advanced solid tumors. This product is the first globally to be developed using a high-affinity hierarchical assembly technology platform, originating from China, targeting various solid tumors. The company holds a 23.8095% stake in Liangyuan Biopharmaceutical, and this research and development progress is beneficial for consolidating the company's first-mover advantage in the precision medicine field and enhancing its core competitiveness